CoChat

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

Open access
Kimura, Kiminori, Ikoma, Akemi, Shibakawa, Maki, Shimoda, Shinji, Harada, Kenichi, Saio, Masanao, Imamura, Jun, Osawa, Yosuke, Kimura, Masamichi, Nishikawa, Koji, Okusaka, Takuji, Morita, Satoshi, Inoue, Kazuaki, Kanto, Tatsuya, Todaka, Koji, Nakanishi, Yoichi, Kohara, Michinori, Mizokami, Masashi · 2017 · EBioMedicine
Cited by 112

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. Methods In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160mg/m 2 /day for six cycles of 1week on and 1week off. The primary endpoints were frequency and severity of adverse events. The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy. This study is registered with ClinicalTrials.gov (no. NCT02195440). Findings Between Sept 3, 2014 and May 2, 2016, 14 patients were enrolled: CP class A:B, 6:8; median age, 62 (range: 43 to 74) years; male:female, 10:4. Twelve of the 14 patients completed six cycles of treatment; one was withdrawn from the study due to possible study drug-related liver injury (grade 3) in the 160mg/m 2 /day dose cohort and one withdrew for personal reasons. Serious adverse events occurred in three patients [21% (3/14)], one of which was possibly related to PRI-724. The most common adverse events were nausea [29% (4/14)] and fatigue [21% (3/14)]. After PRI-724 administration, the CP scores worsened by 1 point in two patients in the 10mg/m 2 /day cohort, improved in three patients at 1, 1, and 2 points in the 40mg/m 2 /day cohort, and improved in one patient by 3 points in the 160mg/m 2 /day cohort. The histology activity index scores of the liver tissue improved in two patients and exacerbated in two patients in the 10mg/m 2 /day cohort, and improved in one patient in the 40mg/m 2 /day cohort. Interpretation This study showed that administration of 10 or 40mg/m 2 /day intravenous PRI-724 over 12weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160mg/m 2 /day cohort. Funding Source AMED.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2017.08.016

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Kimura, K., Ikoma, A., Shibakawa, M., Shimoda, S., Harada, K., Saio, M., Imamura, J., Osawa, Y., Kimura, M., Nishikawa, K., Okusaka, T., Morita, S., Inoue, K., Kanto, T., Todaka, K., Nakanishi, Y., Kohara, M., & Mizokami, M.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2017-09
Volume
23
Pages
79-87
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2747280021
Cited by
112
References
4
FWCI
4.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.